Life Sciences Partner Quoted in Law360 on 2017 Life Sciences Legislation and Regulation to Watch
Life Sciences practice partner Albert Cacozza (Washington, D.C.) was quoted in a Jan. 2 Law360 article on 2017 life sciences legislation and regulation to watch.
Mr. Cacozza explains that a new U.S. Food and Drug Administration (FDA) commissioner, in what is expected to be a deregulated environment under the Trump administration, might be more aggressive in getting guidance about off-label uses for FDA-approved products.
Additionally, the FDA’s user fee acts expire during 2017 and they will have to be reauthorized before the end of the fiscal year because they form the core of the FDA’s budget. He notes that because this is must-pass legislation lawmakers may try to attach desired FDA reforms to the proposals.